Platelet PlA2 polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia

American Journal of Clinical Pathology

Volumn 129, Issue 2, 2008, Pages 282-286

  Harris, Kenneth ^a   Nguyen, Phan ^a   Van Cott, Elizabeth M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Heparin induced thrombocytopenia; HIT; HPA1; PlA2

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN; FIBRINOGEN RECEPTOR; BETA3 INTEGRIN; HEPARIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOSIS; VEIN THROMBOSIS; AGE; CHEMICALLY INDUCED DISORDER; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; RISK; THROMBOCYTOPENIA;

AGE FACTORS; AGED; BLOOD PLATELETS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; PLATELET COUNT; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK; THROMBOCYTOPENIA; THROMBOSIS;

EID: 40449120988     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/BMW4M8NQBV0TKFRX     Document Type: Article

References (23)

1. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1-7.
2. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
3. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56:12-16.
4. Weiss EJ, Bray P F, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-1094.
5. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet. 1997;349:385-388.
6. Zotz RB, Klein M, Dauben H P, et al. Prospective analysis after coronary artery bypass grafting: platelet GP IIIa polymorphism (HPA-1b/PlA2) is a risk factor for bypass occlusion, myocardial infarction, and death. Thromb Haemost. 2000;83:404-407.
7. Zots RB, Windelmann BR, Nauck M, et al. Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost. 1998;79:731-735.
8. A1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost. 1998;80:214-217.
9. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999;94:46-51.
10. A2 polymorphism in siblings of patients with premature coronary heart disease. Arch Pathol Lab Med. 1999;123:1223-1229.
11. Araujo F, Santos A, Araujo V, et al. Genetic risk factors in acute coronary disease. Haemostasis. 1999;29:212-218.
12. A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost. 1997;77:1179-1181.
13. A2 polymorphism. Thromb Haemost. 1998;80:218-219.
14. Laule M, Cascorbi I, Stangl V, et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet. 1999;353:708-712.
15. Bottiger C, Kastrati A, Koch W, et al. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost. 2000;83:559-562.
16. A2 and coronary risk: a meta-analysis. Thromb Haemost. 2001;85:626-633.
17. 3 enhances outside-in signaling and adhesive functions. J Clin Invest. 2000;105;793-802.
18. A polymorphism, fibrinogen, and platelet aggregability: the Framingham Heart Study. Circulation. 2001;104:140-144.
19. Theodoropoulos I, Christopoulos C, Metcalfe P, et al. The effect of human platelet alloantigen polymorphisms on the in vitro responsiveness to adrenaline and collagen. Br J Haematol. 2001;114:387-393.
20. Cadroy Y, Sakariassen K, Charlet J P, et al. Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood. 2001;98:3159-3161.
21. Lee DH, Warkentin TE, Denomme GA, et al. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia. Thromb Haemost. 1998;79:50-53.
22. Carlsson LE, Lubenow N, Blumentritt C, et al. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics. 2003;13:253-258.
23. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost. 1999;81:625-629.